孙世硕｜徐州医科大学｜学者主页

2026

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhen-Yu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Lian-Tao Li, Xiao-Xiao Liu, P. M. Tang, Qing Zhang

Advancement of science

DOI

2026

Correction: Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2

Guopeng Zhang, Wei Zhang, Xiaohuan Wei, Zhenyu Wang, Fei-Tong Wang, Shishuo Sun, Haiheng Xu, Xiang-Ye Liu, Qing Zhang, Xiaoge Gao

Cancer Immunology and Immunotherapy

DOI

2026

Tumor Microenvironment and CAR-T Cell Therapy: Challenges, Breakthroughs, and Future Perspectives

Chen Hu, Ying Xue, Shishuo Sun

Journal of experimental pathology

DOI

2026

HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling

Shishuo Sun, Wanxin Zhao, Yibing Liang, Ying Xue, Qihong Li, Yifan Yuan, Zhenyu Wang, Xiaoge Gao, Yizhou Yao, Haiheng Xu, Hailong Li, Xiao-Xiao Liu, P. M. Tang, Junnian Zheng, Qing Zhang

Cell Communication and Signaling

DOI

2026

Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2

Guopeng Zhang, Wei Zhang, Xiaohuan Wei, Zhenyu Wang, Fei-Tong Wang, Shishuo Sun, Haiheng Xu, Xiang-Ye Liu, Qing Zhang, Xiaoge Gao

Cancer Immunology and Immunotherapy

DOI

2025

Emerging roles of EGFL family members in neoplastic diseases: Molecular mechanisms and targeted therapies.

Xiaoge Gao, Guopeng Zhang, Fei-Tong Wang, Wen-Hui Ruan, Shishuo Sun, Qing Zhang, Xiang-Ye Liu

Biochemical Pharmacology

DOI

2024

Cabozantinib enhances CAIX specific CAR-T cells against renal cancer by improving effector functions and augmenting tumor immune microenvironment.

Qihong Li, Lin Yang, Shuyu Li, Wanxin Zhao, Ying Xue, Zhu-Cheng Lu, Jingwei Tang, Xiaoge Gao, Junnian Zheng, Qing Zhang, Shishuo Sun

Biochemical and Biophysical Research Communications - BBRC

DOI

2024

Tumor angiogenesis and anti-angiogenic therapy

Zi-Heng Guo, Xu Jing, Xiao-Ting Sun, Shishuo Sun, Yunlong Yang, Yi-Hai Cao

Chinese Medical Journal

DOI

2024

Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy.

Wanxin Zhao, Yizhou Yao, Qihong Li, Ying Xue, Xiaoge Gao, Xiang-Ye Liu, Qing Zhang, Junnian Zheng, Shishuo Sun

Biochemical Pharmacology

DOI

2023

DHA attenuates CAR-T cell efficacy through aggravating exhaustion and inducing apoptosis

Yifei Wang, Yuxiao Zhao, Yizhang Zhu, Heng Xu, Wanxin Zhao, Chao Huang, Bixi Wang, Xiao-Ge Gao, Qing Zhang, Junnian Zheng, Shishuo Sun

Biologia

DOI

2023

Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity

Xiao-Ge Gao, Pinlu Jiang, Xiaohuan Wei, Wei Zhang, Ji-Wei Zheng, Shishuo Sun, H. Yao, Xiang-Ye Liu, Qing Zhang

BMC Cancer

DOI

2023

PA suppresses antitumor immunity of T cells by disturbing mitochondrial activity through Akt/mTOR-mediated Ca2+ flux.

Shishuo Sun, Heng Xu, Wanxin Zhao, Qihong Li, Yifan Yuan, Guopeng Zhang, Shuyu Li, Bixi Wang, Wei Zhang, Xiaoge Gao, Junnian Zheng, Qing Zhang

Cancer Letters

DOI

2023

Herpes virus entry mediator costimulation signaling enhances CAR-T cell efficacy against solid tumors through metabolic reprogramming.

Shishuo Sun, Chao Huang, Mengmeng Lu, Heng Xu, Yifan Yuan, Wanxin Zhao, Xiaolei Hu, Bixi Wang, W. Zhang, Xiao-Ge Gao, Junnian Zheng, L. Su, Qing Zhang

Cancer immunology research

DOI

2023

Correction: Novel fusion protein PK5-RL-Gal-3 C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity

Xiao-Ge Gao, Pinlu Jiang, Xiaohuan Wei, Wei Zhang, Ji-Wei Zheng, Shishuo Sun, H. Yao, Xiang-Ye Liu, Qing Zhang

BMC Cancer

DOI

2022

Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs

Xiaokang Zhang, Shishuo Sun, Yangna Miao, Yifan Yuan, Wanxin Zhao, Hailong Li, Xiaohuan Wei, Chao Huang, Xiaolei Hu, Bixi Wang, Heng Xu, Wei Zhang, Xiao-Ge Gao, Jingyuan Song, Junnian Zheng, Qing Zhang

Journal of Cancer Research and Clinical Oncology

DOI

2021

Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity

Hong-Yan Liu, Shishuo Sun, Gang Wang, Mengmeng Lu, Xiaokang Zhang, Xiaohuan Wei, Xiao-Ge Gao, Chao Huang, Zhen Li, Jun-Nian Zheng, Qing Zhang

Frontiers in Oncology

DOI

2021

Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer.

Mengmeng Lu, Xiaokang Zhang, Xiao-Ge Gao, Shishuo Sun, Xiaohuan Wei, Xiaolei Hu, Chao Huang, Heng Xu, Bixi Wang, Wei Zhang, Zhen Li, Xin-Hui Feng, Jun-Nian Zheng, Qing Zhang

Pharmacological Research

DOI

2019

Akt inhibition at the initial stage of CAR-T preparation enhances the CAR-positive expression rate, memory phenotype and in vivo efficacy.

Qing Zhang, Jiage Ding, Shishuo Sun, Hong-Yan Liu, Mengmeng Lu, Xiaohuan Wei, Xiao-Ge Gao, Xiaokang Zhang, Q. Fu, Jun-Nian Zheng

American Journal of Cancer Research

2019

Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells.

Qing Zhang, Hong-Yan Liu, Hanhan Wang, Mengmeng Lu, Yangna Miao, Jiage Ding, Hui-Zhong Li, Xiao-Ge Gao, Shishuo Sun, Jun-Nian Zheng

American Journal of Cancer Research

孙世硕

精选作品

期刊论文

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Correction: Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2

Tumor Microenvironment and CAR-T Cell Therapy: Challenges, Breakthroughs, and Future Perspectives

HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling

Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2

Emerging roles of EGFL family members in neoplastic diseases: Molecular mechanisms and targeted therapies.

Cabozantinib enhances CAIX specific CAR-T cells against renal cancer by improving effector functions and augmenting tumor immune microenvironment.

Tumor angiogenesis and anti-angiogenic therapy

Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy.

DHA attenuates CAR-T cell efficacy through aggravating exhaustion and inducing apoptosis

Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity

PA suppresses antitumor immunity of T cells by disturbing mitochondrial activity through Akt/mTOR-mediated Ca2+ flux.

Herpes virus entry mediator costimulation signaling enhances CAR-T cell efficacy against solid tumors through metabolic reprogramming.

Correction: Novel fusion protein PK5-RL-Gal-3 C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity

Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs

Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity

Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer.

Akt inhibition at the initial stage of CAR-T preparation enhances the CAR-positive expression rate, memory phenotype and in vivo efficacy.

Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells.

研究方向